Vodobatinib New

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP43522CAS No. ：1388803-90-4Purity：98%

Get Quotation Now

Tel: 0086-17754423994 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	1388803-90-4	Cat. No.	BCP43522
Name	Vodobatinib
Synonyms	K-0706; K0706; K0706;
SMILES	CC1=C(C(=CC=C1)Cl)C(=O)NNC(=O)C2=CC(=C(C=C2)C)C#CC3=CC4=CC=CC=C4N=C3
Chemical Name
Formula	C27H20ClN3O2	M. Wt	453.92
Purity	98%	Storage	Store at 4-8°C
Description	Vodobatinib is an orally bioavailable, Bcr-Abl tyrosine kinase inhibitor (TKI), with potential antineoplastic activity. Upon administration, vodobatinib selectively targets and binds to the Bcr-Abl fusion oncoprotein, including various Bcr-Abl mutant forms, such as those with the 'gatekeeper' resistance mutation T315I. This inhibits proliferation of Bcr-Abl-expressing tumor cells. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells. T315I, an amino acid substitution where threonine (T) has been mutated to isoleucine (I) at position 315 in the tyrosine-protein kinase ABL1 portion of the Bcr-Abl fusion protein, plays a key role in resistance to certain chemotherapeutic agents and its expression is associated with poor prognosis.